Skip to main content

Table 1 Demographic and clinical data of the included sarcoidosis patients according to exposure category

From: Associations between occupational and environmental exposures and organ involvement in sarcoidosis: a retrospective case-case analysis

 

Overall (n = 238)

Exposure

Reactive chemical (n = 26)

Inorganic dust (n = 74)

Organic dust (n = 63)

Contact with livestock (n = 15)

Close human contact (n = 31)

Admin work only (n = 42)

Active smoker (n = 43)

Demographics

 Gender

  Women

84 (35%)

5 (19%)§

3 (4.1%)*

22 (35%)

6 (40%)

25 (81%)*

22 (52%)*

9 (21%)*

  Men

154 (65%)

21 (81%)§

71 (96%)*

41 (65%)

9 (60%)

6 (19%)*

20 (48%)*

34 (79%)*

 Age at diagnosis

42 (35–50)

37 (34–49)

41 (35–48)

39 (34–48)§

47 (38–52)

44 (39–50)

42 (36–46)

38 (30–46)*

Smoking

 Never smoker

148 (62%)

14 (54%)

40 (54%)§

43 (68%)

14 (93%)*

21 (68%)

30 (71%)

0 (0%)

 Past smoker

47 (20%)

6 (23%)

17 (23%)

13 (21%)

1 (6.7%)

5 (16%)

6 (14%)

0 (0%)

 Active smoker

43 (18%)

6 (23%)

17 (23%)

7 (11%)§

0 (0%)§

5 (16%)

6 (14%)

43 (100%)

 Packyears (for past or active smokers)

10 (5–20)

7.5 (5–20)

10 (5–20)

12 (5–20)

45

5 (5–14)

10 (9–15)

10 (6–20)

Chest CT at diagnosis

 Enlarged hilar/mediastinal lymph nodes

235 (99%)

25 (96%)

73 (99%)

63 (100%)

15 (100%)

31 (100%)

40 (95%)§

43 (100%)

 (Micro)nodules

183 (77%)

21 (81%)

55 (74%)

51 (81%)

10 (67%)

22 (71%)

35 (83%)

36 (84%)

 Fibrotic changes

13 (5.5%)

2 (7.7%)

4 (5.4%)

2 (3.2%)

0 (0%)

2 (6.5%)

5 (12%)§

4 (9.3%)

 Airway abnormalities

44 (18%)

7 (27%)

20 (27%)*

9 (14%)

1 (6.7%)

3 (9.7%)

8 (19%)

10 (23%)

Lung function at diagnosis

 FVC %pred

94 (85–105)

91 (77–102)

94 (81–103)

90 (78–98)*

94 (91–103)

99 (86–108)

94 (90–108)§

94 (81–106)

 FEV1%pred

89 (76–102)

84 (70–98)

89 (75–104)

82 (71–92)*

92 (87–98)

90 (77–102)

94 (80–106)

81 (70–99)§

 FEV1/FVC%

78 (73–83)

76 (62–82)§

77 (74–82)

76 (70–80)*

80 (77–82)

81 (71–85)

80 (76–83)§

78 (67–83)

 TLC %pred

92 (83–100)

88 (80–99)

89 (80–98)§

86 (80–98)§

91 (86–97)

94 (89–102)

96 (88–100)§

86 (80–101)

 TLCO %pred

80 (68–92)

74 (64–93)

81 (67–95)

80 (68–88)

84 (74–96)

81 (68–87)

79 (69–90)

73 (62–89)*

Broncho-alveolar lavage

 % Lymphocytes

17 (10–25)

19 (14–25)

15 (10–21)

15 (10–23)

13 (7–33)

18 (11–32)

15 (7–25)

14 (7–21)

  Not available

125 (53%)

13 (50%)

34 (46%)

27 (43%)

9 (60%)

20 (65%)

24 (57%)

21 (49%)

Treatment

 Treated within first year after diagnosis

118 (50%)

10 (38%)

41 (55%)

33 (52%)

5 (33%)

16 (52%)

21 (50%)

26 (60%)

  Oral corticosteroids

116 (49%)

10 (38%)

41 (55%)

33 (52%)

5 (33%)

16 (52%)

19 (45%)

26 (60%)§

  Methotrexate

46 (19%)

5 (19%)

17 (23%)

14 (22%)

0 (0%)§

5 (16%)

7 (17%)

16 (37%)*

  Azathioprine

47 (20%)

6 (23%)

17 (23%)

15 (24%)

1 (6.7%)

5 (16%)

10 (24%)

14 (33%)*

  Chloroquine

27 (11%)

4 (15%)

12 (16%)

8 (13%)

0 (0%)

3 (9.7%)

4 (9.5%)

10 (23%)*

  1. Statistics presented: median (25–75%), n (%); Statistical tests performed, comparing exposed to non-exposed: Wilcoxon rank sum test, Fisher’s exact test or Pearson’s Chi-squared test; * when p < 0.05, §p < 0.10